Zhao et al. reported that the GLP-1R activation in response to liraglutide treatment in human pancreatic cancer cell lines and a mouse xenograft model was associated with inhibiting the pancreatic cancer growth and increased apoptosis via the inhibition of Akt and ERK1/2 signaling pathways [31]. The gene discussed is MAPK3; the disease is familial pancreatic carcinoma.